Clinical Trials – Open Recruiting in Florida

  1. Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
    Principal Investigator: Mayer Fishman, M.D., Ph.D.
    ClinicalTrials.gov ID#: NCT02964078
    Location: Hem-Onc Associates of Treasure Coast
    Port Saint Lucie, Florida, United States, 34952
    Status: Recruiting
    Contact: Cortlin Croft
    Phone: 813-745-7559
    Email: cortlin.croft@moffitt.org
  2. Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
    Principal Investigator: Nikhil I Khushalani, MDH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    ClinicalTrials.gov ID#: NCT02718066
    Location: University of Florida, Gainesville, Florida, United States
    University of Miami, Miami, Florida, United States
    Moffitt Cancer Center, Tampa, Florida, United States
    Status: Recruiting
    Contact: Heather Yecks-Rodin, MD
    Phone:
    Email:
  3. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
    Principal Investigator:
    ClinicalTrials.gov ID#: NCT01806064
    Location: “University of Florida” – Gainesville, Florida, United States
    University of Miami – Miami, Florida, United States
    Moffitt Cancer Center – Tampa, Florida, United States”Status: Recruiting
    Contact:
    Phone:
    Email:  Clinicaltrials@traconpharma.com
  4. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
    Principal Investigator: Winston W. Tan
    ClinicalTrials.gov ID#: NCT01767636
    Location: Mayo Clinic
    Jacksonville, Florida, United States, 32224-9980
    Status: Recruiting
    Contact: Clinical Trials Referral Office
    Phone: 855-776-0015
    Email:
  5. A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
    Principal Investigator:
    ClinicalTrials.gov ID#: NCT02915783
    Location: H. Lee Moffitt Cancer Center
    Status:
    Contact: Eisai Medical Services
    Phone: 1-888-274-2378
    Email: esi_medinfo@eisai.com
  6. A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
    ClinicalTrials.gov ID#: NCT03024996
    Principal Investigator:
    Location: Univ of Miami, School of Med; Hem/Onc
    Miami, Florida, United States, 33136
    Moffitt Cancer Center
    Tampa, Florida, United States, 33612
    Status:
    Contact: www.roche.com/about_roche/roche_worldwide.htm
    Phone: 888-662-6728 (U.S. and Canada)
    Email: global-roche-genentech-trials@gene.com
  7. A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
    ClinicalTrials.gov ID#: NCT02684006
    Principal Investigator:
    Location: Moffitt Cancer Center and Research Institute Tampa Florida, 33612
    Status: Recruiting
    Contact: Pfizer CT.gov Call Center
    Phone: 1-800-718-1021
    Email:
  8. Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
    Clinical Trials.gov ID: NCT01727336
    Principal Investigator:
    Location: H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida, United States

    Status: Recruiting
    Contact: Clinical Trials Manager 
    Phone:
    Email: dalanterceptclinicaltrials@acceleronpharma.com
  9. Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
    ClinicalTrials.gov ID: NCT02667886
    Principal Investigator:
    Location: Jacksonville, Florida, United States
    Status: Recruiting
    Contact: Sarah Blanchette, PhD
    Phone:
    Email: patientinfo@x4pharma.com
  10. A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
    ClinicalTrials.gov ID:
    NCT02982954
    Principal Investigator: Bristol-Myers Squibb
    Location: Florida Cancer Specialists S.
    Fort Myers, Florida, United States, 33901
    Orlando Health, Orlando, Florida, United States, 32806
    Status: Recruiting
    Contact: 
    Phone:
    Email: Clinical.Trials@bms.com
  11. Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT02811861
    Principal Investigator:
    Location: University of Miami
    Miami, Florida, United States
    Status: Recruiting
    Contact: Eisai Medical Information
    Phone: 1-888-274-2378
    Email: esi_medinfo@eisai.com
  12. An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT03029780
    Principal Investigator:
    Location: Cancer Specialists of North FL
    Jacksonville, Florida, United States, 32256
    Status: Recruiting
    Contact: Bijoy Telivala, Site 0010 
    Phone: 1-888-274-2378
    Email: 
  13. Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
    ClinicalTrials.gov ID:
    NCT02853344
    Principal Investigator: Merck Sharp & Dohme Corp.
    Location: Call for Information (Investigational Site 8007)
    Miami, Florida, Unitd States,33143
    Status: Recruiting
    Contact:
    Phone: 1-888-577-8839
    Email: 
  14. Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    ClinicalTrials.gov ID:
    NCT02761057
    Principal Investigator: Michael A. Schwartz
    Location: Mount Sinai Medical Center
    Miami Beach, Florida, United States, 33140
    Status: Recruiting
    Contact: Michael A. Schwartz
    Phone: 305-674-2625 
    Email: info@msccop.com
  15. Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
    ClinicalTrials.gov ID:
    NCT01164228
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: Mayo Clinic – Jacksonville
    Jacksonville, Florida, United States, 32224
    Status: Recruiting
    Contact:
    Phone: 507-538-7623 
    Email:
  16. A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
    ClinicalTrials.gov ID:
    NCT02293980
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136, 305-243-1287
    Status: Recruiting
    Contact: Richard Kelley
    Phone: 972-629-4081  
    Email: clinicalstudies@pelotontx.com
  17. A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
    ClinicalTrials.gov ID:
    NCT02627963
    Principal Investigator: Naomi S. Balzer-Haas,
    MD Abramson Cancer Center,University of Pennsylvania
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136
    Status: Recruiting
    Contact: Darlene Wilson, dwilson@aveooncology.com
    Michael Needle, MD mneedle@aveooncology.com
    Phone:  
    Email: See above
  18. A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors
    ClinicalTrials.gov ID:
    NCT02576665
    Principal Investigator: Jaime R Merchan, MDUniversity of Miami
    Location: University of Miami – Sylvester Comprehensive Cancer Center Recruiting
    Miami, Florida, United States, 33136
    Status: Recruiting
    Contact: Jamie Merchan, MD 305-243-1287 jmerchan2@med.miami.edu
    Tamara Leon Aliz (305) 243-0865 txl351@med.miami.edu
    Phone: See above
    Email: See above
  19. A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
    ClinicalTrials.gov ID:
    NCT02599324
    Principal Investigator: Mehdi M Moezi, MD
    Location: Cancer Specialists, LLC, Department of Clinical Research Recruiting
    Jacksonville, Florida, United States, 32256
    Status: Recruiting
    Contact: Jenni Bachhofer 904-363-7462 ext 1179 Jenni.Bachhofer@CSNF.us
    Judy Bulacan 904-264-6201 Judy.Bulacan@CSNF.us
    Phone: See above
    Email: See above
  20. Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
    ClinicalTrials.gov ID:
    NCT01261728
    Principal Investigator: Memorial Sloan Kettering Cancer Center
    Location: Baptist Alliance MCI Recruiting
    Miami, Florida, United States, 33143
    Status: Recruiting
    Contact: Antonio Muina, MD
    Phone: 786-596-2000
    Email: 
  21. Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
    ClinicalTrials.gov ID:
    NCT02071862
    Principal Investigator: Manish R Patel, MD
    Location: Florida Cancer Specialists
    Sarasota, Florida, United States, 34232
    Status: Recruiting
    Contact:
    Phone: 941-377-9993
    Email: 
  22. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
    ClinicalTrials.gov ID:
     NCT02568267
    Principal Investigator:  Christine Chung, MD
    Location: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Tampa, Florida, United States, 33612
    Status: Recruiting
    Contact: Ignyta Inc.
    Phone: 1-844-782-7875
    Email: STARTRKtrials@ignyta.com
  23. Safety Study of MGA271 in Refractory Cancer
    ClinicalTrials.gov ID:
    NCT01391143
    Principal Investigator:  Christine Chung, MD
    Location: Moffitt Cancer Center Recruiting
    Tampa, Florida, United States, 33612
    Status: Recruiting
    Contact: Allison Richards, MS  
    Phone: 813-745-8352
    Email: allison.richards@moffitt.org